Identifying the genetic variants and underlying mechanisms that cause neuropsychiatric disease is the key to personalized therapy. But achieving that goal requires an interdisciplinary team of experts, and access to population-level data sets. The Mount Sinai Department of Psychiatry’s new Center for Disease Neurogenomics is in the unique position of having both.